Brief: Epigenomics 9-mth Adj. EBITDA At EUR -8.1 Mln

Epigenomics AG

12/11/2020 07:49

Nov 12 (Reuters) - EPIGENOMICS AG  ECXn.DE :
    * REPORTS FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF
2020
    * 9M REVENUE 541,000 EUR
    * TOTAL REVENUE IN FIRST NINE MONTHS OF 2020 WAS EUR 541
THOUSAND
COMPARED TO EUR 847 THOUSAND FOR SAME PERIOD OF PREVIOUS YEAR
    * OVERALL, OPERATING COSTS FELL FROM EUR 13.4 MILLION TO EUR
10.9
MILLION COMPARED TO FIRST NINE MONTHS 2019 FOR REASONS MENTIONED
ABOVE
    * ADJUSTED EBITDA (BEFORE SHARE-BASED PAYMENT EXPENSES) FOR
FIRST
NINE MONTHS OF 2020 WAS EUR -8.1 MILLION (9M 2019: EUR -9.7
MILLION)
    * 9-MONTH NET LOSS FOR PERIOD IMPROVED TO EUR 9.1 MILLION
(9M
2019: EUR 10.0 MILLION)
    * HAS NOW REVISED ITS GUIDANCE FOR ADJUSTED EBITDA BEFORE
SHARE-BASED PAYMENT EXPENSES AND CASH CONSUMPTION UPWARD AS COST
REDUCTION PROGRAMS INITIATED IN SPRING ARE NOW SHOWING
SIGNIFICANT RESULTS
    * FY EBITDA BEFORE SHARE-BASED PAYMENT EXPENSES IS EXPECTED
TO BE
WITHIN A RANGE OF EUR -10.0 MILLION TO EUR -11.0 MILLION
(PREVIOUSLY: EUR -10.5 MILLION TO EUR -12.5 MILLION)

Source text for Eikon:  ID:nEQ7mH3PQa 
Further company coverage:  ECXn.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))